

***IN VITRO AND IN VIVO* STUDY ON THE
IDENTIFICATION OF COMPOUNDS THAT
ALLEVIATE A β 42 ASSOCIATED
NEURODEGENERATION**

FLORENCE TAN HUI PING

UNIVERSITI SAINS MALAYSIA

2020

***IN VITRO* AND *IN VIVO* STUDY ON THE
IDENTIFICATION OF COMPOUNDS THAT
ALLEVIATE A β 42 ASSOCIATED
NEURODEGENERATION**

by

FLORENCE TAN HUI PING

**Thesis submitted in fulfilment of the requirements
for the degree of
Doctor of Philosophy**

December 2020

ACKNOWLEDGEMENT

First and foremost, I would like to express my sincerest gratitude towards Dr Ghows Azzam for the continuous support, advice and knowledge throughout my doctoral research. Also, to my co-supervisors, Prof Nazalan Najimudin and Prof Watanabe Nobumoto, thank you for the inspiration and insightful comments that have helped build my thesis.

Not to be forgotten, I extend my deepest appreciation to my fellow colleagues of Ghows Lab and Nazalan Lab. From long hours of executing experiments together in the laboratory to brain-storming on ideas, thank you for sharing your experiences with me. To Woo Wai Kan, Andrew Ting Chung Jie and the rest of the gang, it has been a joy working with every one of you.

Special thanks to the staff of USM's School of Biological Sciences and the Chemical Biology Research Group in RIKEN for their indispensable assistance in the project. I would also like to thank my esteemed sponsors MybrainSc and USM-RIKEN International Centre for Ageing Science (URICAS), for it is through their funding that has granted me the opportunity to further pursue my studies, both locally and internationally.

To my dearest parents and family who have been with me from the very start, there are no words to express my gratitude for the love, patience and sacrifices made to get me where I am now. Last but not least, thank you to my partner and lifelong friend, Tan Siew Heng for the encouragement and affection that you have showered me throughout my journey.

I would not have made it this far without any of you. Thank you for everything.

TABLE OF CONTENTS

ACKNOWLEDGEMENT	ii
TABLE OF CONTENTS	iii
LIST OF TABLES	x
LIST OF FIGURES	xiii
LIST OF ABBREVIATIONS	xvii
LIST OF APPENDICES	xxi
ABSTRAK	xxii
ABSTRACT	xxiv
CHAPTER 1 GENERAL INTRODUCTION	1
1.1 Overview.....	1
1.2 Objectives.....	2
1.3 Outline.....	3
CHAPTER 2 LITERATURE REVIEW	5
2.1 The ageing tsunami– A global concern.....	5
2.1.1 Ageing and dementia.....	5
2.2 Alzheimer’s Disease – The plight of forgetfulness.....	7
2.3 Genetics of AD.....	7
2.3.1 Early onset familial Alzheimer’s disease (EOFAD)	8
2.3.1(a) Amyloid precursor protein (APP)	9
2.3.1(b) Presenilin (PS)	12
2.3.2 Late onset Alzheimer’s disease (LOAD)	13
2.4 Amyloid pathway hypothesis	14
2.4.1 A β production, oligomerization and fibrillization	15
2.4.1(a) A β proteins – its normal physiology and toxic forms	17
2.5 Animal models of AD.....	21

2.5.1	<i>Drosophila melanogaster</i> : A comprehensive model.....	23
2.5.1(a)	<i>Drosophila</i> as a model for neuroresearch.....	25
2.5.1(b)	Setbacks in using the <i>Drosophila</i>	28
2.5.2	Establishing <i>Drosophila</i> as an AD model.....	28
2.6	Potential therapeutic studies targeting amyloid.....	35
2.6.1	Therapies for A β Aggregation inhibitors.....	35
2.6.2	Anti-oxidant therapies for AD.....	37
2.6.3	<i>Drosophila melanogaster</i> as a drug screening tool.....	37
2.7	The miracle root, Danshen (<i>Salvia miltiorrhiza</i>)	39
2.7.1	Salvianolic acids studies in combating dementia.....	40
CHAPTER 3		
	<i>IN VITRO</i> SCREENING FOR Aβ42 AGGREGATION INHIBITORS.....	43
3.1	Introduction and rationale.....	43
3.2	Methodology.....	45
3.2.1	Plasmid Source.....	46
3.2.2	Crude genomic DNA extraction.....	46
3.2.3	Polymerase Chain Reaction (PCR) of A β 42 sequence.....	47
3.2.4	Purification of the amplified A β 42 fragment.....	50
3.2.5	Cloning of pET21- A β 42.....	50
3.2.5(a)	Restriction digestion of the A β 42 fragment.....	50
3.2.5(b)	Restriction digest of pET21a(+) plasmid.....	51
3.2.5(c)	Ligation of restricted pET21a(+) plasmid and A β 42 fragment.....	52
3.2.6	Transformation of recombinant plasmids into <i>E. coli</i> BL21 strain competent cells.....	52
3.2.6(a)	Transformant screening by colony PCR.....	53
3.2.7	Plasmid Extraction	53
3.2.8	Expression of histidine-tagged A β 42 in pET21a-A β 42.....	54
3.2.9	Cell lysis.....	55

3.2.10	Immobilized Affinity Column Chromatography (IMAC).....	55
3.2.11	Sodium dodecyl sulphate-PAGE (SDS-PAGE) analysis.....	56
3.2.12	A β 42 Aggregation assay	58
3.3	Results	59
3.3.1	Preparation of histidine-tagged A β 42 peptides for chemical array assay	59
3.3.2	Screening of small molecules via the chemical array assay.....	66
3.3.3	Screening of small molecules and DWE constituents using the A β 42 aggregation assay.....	68
3.4	Discussion.....	79
3.4.1	<i>E. coli</i> BL21 (DE3) strain as the expression host.....	79
3.4.2	pET21a(+) as the plasmid for A β 42 peptide production.....	80
3.4.3	Expression of pET21a-A β 42 yielded histidine-tagged A β 42 in the inclusion bodies	82
3.4.4	Purification of histidine-tagged A β 42 using Immobilized metal affinity chromatography (IMAC) purified histidine-tagged A β 42.....	83
3.4.5	Chemical array as the assay to screen for A β 42 ligands	84
3.4.6	Thioflavin T dye as an indicator for A β 42 fibrilization.....	85
3.4.7	A β aggregation assay identified A β aggregation inhibitors.....	87
3.4.8	Effects of DWE and its components on the A β aggregation assay	87
3.4.9	Clustering of A β 42 aggregation inhibitors and implications for future work.....	88

CHAPTER 4 SCREENING OF COMPOUNDS THAT PROTECTS CELLS FROM A β 42-INDUCED CELL DEATH90

4.1	Introduction and background.....	90
4.2	Methodology.....	91
4.2.1	Preparation of A β 42.....	91
4.2.2	Cell culture husbandry.....	92
4.2.3	PC12 Cell differentiation.....	92
4.2.4	WST cell viability assay.....	93

4.2.5	ATP cell viability assay.....	95
4.3	Results.....	96
4.3.1	Induction of neurite growth in PC12 cells and A β 42 incubation	96
4.3.2	Optimization of WST-8 assay.....	98
4.3.3	Optimization of ATP-based cell viability assay.....	102
4.3.4	Compound screening ATP assay.....	105
4.4	Discussion.....	108
4.4.1	PC12 neuronal cells as the cell model to study A β 42-related toxicity.....	108
4.4.2	Usage of WST-8 based colorimetric assay to study cell viability.....	110
4.4.2(a)	Setbacks of the WST-8 based assay and its failure to be used for this study.....	111
4.4.3	ATP-based luminometric assay as the preferred system to analyse cell viability in this study	113
CHAPTER 5	<i>Drosophila melanogaster</i> AS THE ANIMAL MODEL FOR SCREENING COMPOUNDS AGAINST Aβ42-ASSOCIATED PHENOTYPES.....	116
5.1	Introduction and background.....	116
5.2	Methodology.....	118
5.2.1	<i>Drosophila</i> Stocks and Husbandry	118
5.2.2	UPLC analysis	121
5.2.3	External eye surface digital imaging and phenotypic analysis for the neurotoxicity assay	122
5.2.4	Establishment of the CAFE assay.....	123
5.2.5	Survivability analysis.....	124
5.2.6	Establishment of the negative geotaxis examination	125
5.3	Results	127
5.3.1	Comparison of driver lines using the survivability analysis	127
5.3.2	Optimization of the CAFE assay	130

5.3.3	Optimization of the negative geotaxis examination.....	137
5.3.4	Screening of DWE and its constituents.....	140
5.3.4(a)	Measurement of DWE water extract active compounds in fed <i>Drosophila</i>	140
5.3.4(b)	Neurotoxicity assay of <i>Drosophila melanogaster</i> AD model when fed with DWE, SalA and SalB.....	142
5.3.4(c)	Lifespan of AD <i>Drosophila</i> with feeding of DWE, SalA and SalB.....	146
5.3.4(d)	Negative geotaxis examination analysis on <i>Drosophila</i> fed with DWE and its constituents	153
5.3.5	Screening of selected small molecules from NPdepo library.....	157
5.3.5(a)	Neurotoxicity assay of <i>Drosophila melanogaster</i> AD model when fed with selected small molecules from NPdepo library.....	157
5.3.5(b)	Lifespan of AD <i>Drosophila</i> with feeding of NPD6990	161
5.3.5(c)	Negative geotaxis examination analysis on <i>Drosophila</i> fed NPD6990.....	165
5.4	Discussion	167
5.4.1	Optimization of <i>Drosophila</i> behavioural assays.....	167
5.4.1(a)	The <i>Drosophila</i> eye as a screening platform and quantification of REP degeneration.....	167
5.4.1(b)	The designation of Actin5C-GAL4 as the selected driver line to study the effects of A β 42 expression.....	167
5.4.1(c)	The employment of the CAFE assay and its effect on the survivability and negative geotaxis analyses	170
5.4.1(d)	Establishment of the negative geotaxis examination...	179
5.4.2	Screening of DWE, SalA and SalB using the AD <i>Drosophila</i> mode	175
5.4.2(a)	SalA and SalB were detected in the brains and bodies of <i>Drosophila</i> after DWE feeding.....	175
5.4.2(b)	Administration of DWE, SalA and SalB amended the REP, extended the lifespan and improved the locomotive ability of the <i>Drosophila melanogaster</i> AD model	176

5.4.3	NPD6990 countermanded ill-effects induced by A β 42 in the <i>Drosophila</i>	178
-------	--	-----

CHAPTER 6 TRANSCRIPTOMIC RESPONSE OF THE AD *Drosophila* MODEL TOWARDS SALVIANOLIC ACID A, SALVIANOLIC ACID B AND NPD6990.....179

6.1	Introduction and rationale.....	179
6.2	Materials and Methods	180
6.2.1	Experimental design.....	180
6.2.2	Preparation of total RNA samples.....	181
6.2.3	RNA sequencing pipeline.....	182
6.2.3(a)	Sample quality control.....	182
6.2.3(b)	Library construction and sequencing.....	182
6.2.3(c)	Quality control on sequencing output.....	183
6.2.3(d)	Quality check on the raw reads.....	183
6.2.3(e)	Alignment of raw reads to reference genome.....	183
6.2.3(f)	Counting reads per genes.....	183
6.2.3(g)	Differential expression analysis.....	184
6.2.3(h)	GO and KEGG enrichment analysis of DEGs.....	184
6.3	Results	186
6.3.1	Quality and quantity evaluation of RNA samples.....	186
6.3.2	Quality check on the raw reads.....	188
6.3.3	Alignment scores.....	190
6.3.4	Identification of DEGs.....	191
6.3.4(a)	DEG comparison of untreated (Actin5c-A β 42.DMSO) samples against control (Actin5C-OreR.DMSO) Samples.....	191
6.3.4(b)	DEG comparison of SalA (Actin5c-A β 42.SalA) treated samples against untreated (Actin5c-A β 42.DMSO) samples.....	202
6.3.4(c)	DEG comparison of SalB (Actin5c-A β 42.SalB) treated samples against untreated (Actin5c-A β 42.DMSO) Samples.....	205

6.3.4(d)	DEG comparison of NPD6990 (Actin5c-A β 42.NPD6990) treated samples against untreated (Actin5c-A β 42.DMSO) samples	209
6.4	Discussion.....	213
6.4.1	A β 42 expression in the untreated Actin5C-A β 42.DMSO elicited various DEGs compared to the control Actin5C-OreR.DMSO	213
6.4.2	SalA inhibits the production of steroids in response to A β 42 expression	217
6.4.3	SalB upregulated pathways linked to antioxidant activities when compared to the untreated samples.....	218
6.4.4	NPD6990 suppresses the immune response pathway in response to A β 42's toxicity	220
CHAPTER 7	CONCLUDING REMARKS.....	223
REFERENCES		225
APPENDICES		
LIST OF PUBLICATIONS		

LIST OF TABLES

		Page
Table 2.1	List of mutations near to or within the A β region of the APP	11
Table 2.2	Evaluation of common animal models	22
Table 2.3	Genes required for human APP proteolysis, their roles and their <i>Drosophila</i> homolog in addition to the accession number and percentage identity	31
Table 2.4	List of publicly available AD <i>Drosophila</i> models carrying mutations near or within the A β region of the APP	32
Table 3.1	Chemicals and reagents used in chapter 3	45
Table 3.2	DNA sequences used in the plasmid construction.....	49
Table 3.3	Components for the PCR reaction used to amplify A β 42 gene.....	49
Table 3.4	PCR parameters for the amplification of the A β 42 gene.....	49
Table 3.5	Recipes of buffers utilized for cell lysis	55
Table 3.6	Recipe for 16 % Tris-Tricine gel.....	57
Table 3.7	Recipes for buffers employed for SDS-PAGE preparation and analysis	57
Table 4.1	Chemicals and reagents used in chapter 4.....	91
Table 5.1	Assays used to screen DWE and its constituents, and selected small molecules from NPdepo library.....	117
Table 5.2	Chemicals and reagents used in chapter 5	118
Table 5.3	<i>Drosophila</i> lines used in this study.....	120
Table 5.4	Mean and median of male transgenic <i>Drosophila melanogaster</i> carrying the elav-GAL4 or Actin5C-GAL4 driver	128
Table 5.5	Log-rank test of lifespans of male transgenic <i>Drosophila melanogaster</i> carrying the elav-GAL4 or Actin5C-GAL4 driver.....	128
Table 5.6	Mean and median of female transgenic <i>Drosophila melanogaster</i> carrying the elav-GAL4 or Actin5C-GAL4 driver.....	129
Table 5.7	Log-rank test of lifespans of female transgenic <i>Drosophila melanogaster</i> carrying the elav-GAL4 or Actin5C-GAL4 driver.....	129

Table 5.8	Initial and final volumes of liquid feed for two tubes with and without flies	131
Table 5.9	Total average volume of liquid feed required for 10 flies and the amount of evaporated liquid feed in 24 hours	132
Table 5.10	Mean and median of male transgenic <i>Drosophila melanogaster</i> cultured using the conventional solid food versus CAFE assay	134
Table 5.11	Log-rank test of male transgenic <i>Drosophila melanogaster</i> cultured using the conventional solid food versus CAFE assay	134
Table 5.12	Mean and median of female transgenic <i>Drosophila melanogaster</i> cultured using the conventional solid food versus CAFE assay	135
Table 5.13	Log-rank test of female transgenic <i>Drosophila melanogaster</i> cultured using the conventional solid food versus CAFE assay	135
Table 5.14	Mean and median of male transgenic <i>Drosophila melanogaster</i> fed with or without DWE, SalA or SalB	147
Table 5.15	Log-rank test of lifespans of male transgenic <i>Drosophila melanogaster</i> fed with or without DWE, SalA or SalB	149
Table 5.16	Mean and median of female transgenic <i>Drosophila melanogaster</i> fed with or without DWE, SalA or SalB	150
Table 5.17	Log-rank test of lifespans of female transgenic <i>Drosophila melanogaster</i> fed with or without DWE, SalA or SalB	151
Table 5.18	Average climbing speeds of male transgenic <i>Drosophila melanogaster</i> fed with or without DWE, SalA or SalB	155
Table 5.19	Average climbing speeds of female transgenic <i>Drosophila melanogaster</i> fed with or without DWE, SalA or SalB	155
Table 5.20	Mean and median of male transgenic <i>Drosophila melanogaster</i> fed with selected small molecules from NPdepo library	162
Table 5.21	Log-rank test of lifespans of male transgenic <i>Drosophila</i> fed with NPD6990	162
Table 5.22	Mean and median of female transgenic <i>Drosophila melanogaster</i> fed with NPD6990	163
Table 5.23	Log-rank test of lifespans of female transgenic <i>Drosophila</i> fed with NPD6990	163
Table 5.24	Average climbing speeds of male transgenic <i>Drosophila melanogaster</i> fed with or without NPD6990	165
Table 5.25	Average climbing speeds of female transgenic <i>Drosophila melanogaster</i> fed with or without NPD6990	165

Table 6.1	Labelling of samples for RNA sequencing.....	180
Table 6.2	RNA quality and quantity report	187
Table 6.3	RNA-Seq Illumina HiSeq PE150 sequencing output statistics	188
Table 6.4	Top 10 upregulated genes of untreated samples against control	191
Table 6.5	Top 10 downregulated genes of untreated samples against control	192
Table 6.6	Most enriched GO terms and KEGG pathways for upregulated DEGs of untreated samples against control	193
Table 6.7	Most enriched GO terms and KEGG pathways for downregulated DEGs of untreated samples against control samples.....	197
Table 6.8	Top five downregulated genes of SalA samples when compared against untreated samples	203
Table 6.9	Most enriched KEGG pathway for downregulated DEGs of SalA treated samples against untreated samples	203
Table 6.10	Upregulated genes of SalB treated samples when compared against untreated samples	206
Table 6.11	Downregulated genes of SalB treated samples when compared against untreated samples	206
Table 6.12	Most enriched GO terms and KEGG pathways for upregulated DEGs of SalB treated samples against untreated samples.....	207
Table 6.13	Downregulated genes of NPD6990 treated samples when compared against untreated samples	210
Table 6.14	Most enriched GO terms and KEGG pathways for downregulated DEGs of NPD6990 treated samples against untreated samples	210

LIST OF FIGURES

		Page
Figure 2.1	Pathogenic mutations within the A β region of the APP	11
Figure 2.2	APP proteolysis	17
Figure 2.3	Transgenic <i>Drosophila</i> employing the UAS-GAL4 system.....	25
Figure 2.4	A comparison of similar elements of APP proteolysis.....	30
Figure 2.5	Protein sequence of A β 42 and structure of A β 40 & A β 42 fibrils	36
Figure 2.6	The plant and root of <i>Salvia miltiorrhiza</i>	39
Figure 3.1	General workflow for Chapter 3.....	44
Figure 3.2	pET21a(+) structure.....	46
Figure 3.3	pET-21a(+) plasmid map.....	51
Figure 3.4	Gradient PCR amplification of human A β 42 from transgenic <i>Drosophila</i> gDNA	59
Figure 3.5	Recombinant plasmid pET21a-A β 42 plasmid constructed	60
Figure 3.6	Colony PCR amplification of colonies with potential pET21a-A β 42	61
Figure 3.7	Products of colony PCR resolved on 2% TAE agarose gel.....	62
Figure 3.8	DNA sequencing alignment of pET21a-A β 42 versus the human A β 42 sequence.....	63
Figure 3.9	Amino acid sequence of pET21a-A β 42 versus the human A β 42 reference sequence.....	64
Figure 3.10	SDS-PAGE of A β 42 expression.....	65
Figure 3.11	SDS-PAGE of affinity purification	66
Figure 3.12	Schematic representation depicting the mechanism of the chemical array	67
Figure 3.13	Schematic illustration depicting the mechanism of the A β 42 aggregation assay	69
Figure 3.14	First set of A β 42 aggregation assay screening of the 165 A β 42-ligands	70

Figure 3.15	Second set of A β 42 aggregation assay screening of the 165 A β 42-ligands	71
Figure 3.16	Third set of A β 42 aggregation assay screening of the 165 A β 42-ligands	72
Figure 3.17	Fourth set of A β 42 aggregation assay screening of the 165 A β 42-ligands	73
Figure 3.18	Second trial of A β 42 aggregation assay for reproducibility	75
Figure 3.19	A β 42 aggregation assay of DWE and its water soluble constituents	77
Figure 3.20	Clustering of “hit” compounds according to the structure and activity relationship (SAR) analysis	78
Figure 4.1	Timeline of PC12 neurite growth induction	93
Figure 4.2	Timeline of the optimization of PC12 cell morphology using WST assay	94
Figure 4.3	Timeline of WST assay optimization	94
Figure 4.4	Timeline of ATP assay optimization	95
Figure 4.5	Morphological changes of PC12 cells after NGF induction and A β 42 incubation viewed at 20x magnification.....	97
Figure 4.6	Effect of 10 μ M A β 42 towards PC12 cell viability.....	99
Figure 4.7	Verification of WST-based assay viability for this study.....	101
Figure 4.8	Verification of ATP-based assay viability for this study.....	103
Figure 4.9	Results of ATP assay optimization.....	105
Figure 4.10	Results of ATP assay for compound screening	106
Figure 4.11	Results of ATP assay (reproducibility) for compound screening.....	107
Figure 4.12	Selected compounds that were brought back to USM, Penang for further testing	107
Figure 5.1	Schematic diagram on the mounting of <i>Drosophila</i> for light microscopy viewing of the eye.....	122
Figure 5.2	Schematic diagram of the CAFE assay setup	124
Figure 5.3	Actual image and schematic diagram of the negative geotaxis assay setup	126
Figure 5.4	Comparison of lifespans between elav and Actin5C lines	130

Figure 5.5	Comparison of lifespans between Actin5C lines fed with solid food and liquid feed.....	136
Figure 5.6	Schematic representation of the young age, middle age and old age phases of control Actin5C-OreR.DMSO.L and Actin5C- A β 42.DMSO when grown using the CAFE assay	137
Figure 5.7	Comparison of average climbing speeds between control Actin5C-OreR.DMSO with Actin5C-A β 42.DMSO on day 5, day 10 and day 15 after eclosure.....	139
Figure 5.8	UPLC analysis of SalA and SalB	141
Figure 5.9	Comparison of <i>Drosophila</i> eye light micrographs when reared with different concentrations of DWE, SalA and SalB	143
Figure 5.10	Scanning electron micrographs of transgenic <i>Drosophila melanogaster</i> fed DWE and its constituents	145
Figure 5.11	The effect of DWE on the lifespan of transgenic <i>Drosophila melanogaster</i>	152
Figure 5.12	Average climbing speed of AD <i>Drosophila</i> fed with and without compounds at three time points	156
Figure 5.13	Comparison of <i>Drosophila</i> eye light micrographs when reared with different concentrations of NPD6990, NPD14801 and NPD9554	158
Figure 5.14	Scanning electron micrographs of transgenic <i>Drosophila melanogaster</i> fed with potential inhibitors from NPdepo library	160
Figure 5.15	The effect of NPD6990 on the lifespan of transgenic <i>Drosophila melanogaster</i>	164
Figure 5.16	Average climbing speeds of AD <i>Drosophila</i> fed with and without NPD6990 at three time points	166
Figure 6.1	Gel electrophoresis of RNA samples.....	187
Figure 6.2	FastQC analysis on sample reads	189
Figure 6.3	Alignment scores for the sample reads using HISAT2	190
Figure 6.4	Volcano plot of DEGs between untreated samples and control samples.....	188
Figure 6.5	Most enriched GO terms for upregulated DEGs of untreated samples against control.....	190
Figure 6.6	KEGG pathways for upregulated DEGs of untreated samples against control samples	196
Figure 6.7	Most enriched GO terms for downregulated DEGs of untreated samples against control samples.....	198

Figure 6.8	KEGG pathways for downregulated DEGs of untreated samples against control samples	201
Figure 6.9	Volcano plot of DEGs between SalA treated samples and untreated samples	202
Figure 6.10	KEGG pathway of steroid biosynthesis for downregulated DEGs of SalA treated samples against untreated samples	204
Figure 6.11	Volcano plot of DEGs between SalB treated samples against untreated samples	205
Figure 6.12	Most enriched GO terms for upregulated DEGs of SalB treated samples against untreated samples	207
Figure 6.13	KEGG pathway of glutathione metabolism for upregulated DEGs of SalB treated samples against untreated samples.....	208
Figure 6.14	Volcano plot of DEGs between NPD6990 samples and untreated samples	209
Figure 6.15	Most enriched GO terms for downregulated DEGs of NPD6990 treated samples against untreated samples	211
Figure 6.16	KEGG pathway of Toll and Imd pathway for downregulated DEGs of NPD6990 treated samples against untreated samples	212

LIST OF ABBREVIATIONS

μ	micro
ACE	Angiotensin converting enzyme
AD	Alzheimer's disease
ADI	Alzheimer's disease International
AICD	APP intracellular domain
AMP	Antimicrobial peptides
APOE	Apolipoprotein E
APP	Amyloid precursor protein
ATP	Adenosine tri-phosphate
A β	Amyloid-beta
BACE	Beta-secretase
<i>Bgm</i>	<i>Bubblegum</i>
BP	Biological processes
CAFÉ	CApillary FEeder
CC	Cellular components
CNS	Central nervous system
Co ²⁺ -CMA	Co(II)-carboxymethylaspartate
CYP	Cytochrome P450
dAPPI	<i>Drosophila</i> APP-like
dBACE	Beta-secretase-like enzyme
DEG	Differentially expressed gene
DMEM	Dulbecco`s Modified Eagle Media
DMSO	Dimethyl sulfoxide

dPS	<i>Drosophila</i> presenilin homolog
<i>drd</i>	<i>Drop-dead</i>
dTau	<i>Drosophila</i> tau
DWE	Danshen water extract
EGFR	Epidermal growth factor receptor
elav	Embryonal lethal, abnormal vision
EOFAD	Early onset familial Alzheimer's disease
ERK	Extracellular-signal-regulated kinase
FDA	United States Food and Drug Administration
FDR	False discovery rate
GMR	Glass Multiple Reporter
GO	Gene Ontology
GST-tagged	Glutathione S-transferase-tagged
H ₂ O ₂	Hydrogen peroxide
HST	Heat shock protein
Ibs	Inclusion bodies
iCa ²⁺	Intracellular Ca ²⁺
IL	Interleukin
IMAC	Immobilized Affinity Column Chromatography
IPTG	Isopropyl β-D-1-thiogalactopyranoside
KEGG	Kyoto Encyclopedia of Genes and Genomes
LB	Lysogeny broth
LOAD	Late onset Alzheimer's disease
log ₂ FC	log ₂ FoldChnage
m	mili

MAPK	Mitogen-activated protein kinase
MF	Molecular functions
n	nano
NFT	Neurofibrillary tangles
NGF	Nerve Growth Factor
NHMS	National Health and Morbidity Survey
NMDA	N-methyl-D-aspartate
NPDepo	RIKEN Natural Products Depository
Nrf	Nuclear factor erythroid
OreR	Oregon R
PS	Presenilin
RAGE	Receptor for advanced glycation end products
REP	Rough eye phenotype
RFU	Relative Fluorescence Unit
RIKEN	Rikagaku Kenkyūjo
RLU	Relative luminescent unit
RNA-Seq	RNA-sequencing
ROS	Reactive oxygen species
SalA	Salvianolic acid A
SalB	Salvianolic acid B
SAR	structure and activity relationship
<i>sws</i>	<i>Swiss cheese</i>
T7 RNAP	T7 RNA polymerase
THS	Thioflavin S
THT	Thioflavin T

TNF- α	Tumor necrosis factor alpha
UAS	Upstream activator sequence
UPLC	Ultra Performance Liquid Chromatography
USM	Universiti Sains Malaysia
WST	Water-soluble tetrazolium salt

LIST OF APPENDICES

- Appendix A Set-up of the chemical array assay
- Appendix B Chemical array analysis results using human A β 42-tagged proteins
- Appendix C List of genes involved in GO terms for upregulated DEGs of untreated samples against control samples
- Appendix D List of genes involved in GO terms for downregulated DEGs of untreated samples against control samples
- Appendix E List of genes involved in GO terms for downregulated DEGs of SalA treated samples against untreated samples
- Appendix F List of genes involved in GO terms for downregulated DEGs of SalB treated samples against untreated samples
- Appendix G List of genes involved in GO terms for downregulated DEGs of NPD6990 treated samples against untreated samples

KAJIAN *IN VITRO* DAN *IN VIVO* BAGI PENGENALPASTIAN SEBATIAN YANG MENGURANGKAN NEURODEGENERASI KAITAN A β 42

ABSTRAK

Penyakit Alzheimer (AD) adalah penyakit neurologi yang paling biasa di peringkat global. Mekanisme penyakit ini merangkumi pengumpulan plak ekstraselular senil yang terdiri daripada peptida β -amiloid (A β) dalam otak. Antara isomer A β yang dirembeskan di otak, A β 42 adalah yang paling neurotoksik dan agresif. Walaupun terdapat banyak kajian mengenai AD, patogenesis penyakit ini masih belum diketahui. Tujuan utama kajian ini adalah untuk mengenal pasti sebatian yang boleh mengurangkan kesan negatif A β 42. Dua kumpulan sebatian, iaitu molekul kecil daripada perpustakaan RIKEN NPDepo dan konstituen larut air dari ekstrak air Danshen (DWE) telah disaring. Pertama sekali, sebatian ini disahkan dapat mengurangkan agregasi A β 42 berdasarkan ujian agregasi A β 42 *in vitro* yang mengukur kuantiti pembentukan agregat A β 42 dalam masa nyata. Dua puluh sebatian yang dapat mengurangkan agregat A β 42 sehingga kurang daripada 70% kawalan A β 42 yang tidak dirawat dengan sebatian dianggap sebagai penghambat agregasi A β 42 yang berpotensi. Oleh sebab agregasi A β 42 mengakibatkan degenerasi neuron, dua puluh perencat agregasi A β 42 yang berpotensi ini diuji pada sel-sel neuron PC12 yang diinkubasi dengan A β 42. Enam daripada perencat agregasi A β 42 yang berpotensi dapat mengurangkan kematian sel PC12 yang diinkubasi dengan A β 42 secara ketara berbanding sel kawalan PC12 yang tidak terdedah kepada A β 42. Sebatian-sebatian ini kemudian diuji dengan menggunakan *Drosophila melanogaster*. *Drosophila melanogaster* adalah model yang baik untuk menganalisis

ciri fisiologi dan gangguan tingkah laku dalam penyakit neurodegeneratif manusia. Model AD *Drosophila* yang digunakan dalam tesis ini mengekspresi A β 42 manusia. *Drosophila* AD menunjukkan struktur mata yang merosot yang disebut sebagai fenotip mata kasar (REP), penurunan kemampuan lokomotif dan kematian awal. Asid salvianolik A (SalA) (100 μ M), asid salvianolik B (SalB) (100 μ M) dan NPD6990 (100 μ M) didapati dapat memperbaiki sebahagian REP, meningkatkan pergerakan dan memanjangkan jangka hayat apabila makanan yang mengandungi sebatian ini diberi kepada *Drosophila* AD. Oleh sebab kesan penyelamatan yang efektif ini, tindak balas transkriptomik *Drosophila* AD terhadap ketiga-tiga sebatian tersebut dikaji. SalA menghalang gen biosintesis steroid seperti *Lip3* yang mungkin dapat mengurangkan pembentukan plak amiloid dalam otak. Sebaliknya, SalB meningkatkan kepekatan glutathione dalam otak yang meredakan kecederaan oksidatif yang diperburuk oleh A β melalui peningkatan gen yang terlibat dalam sintesis glutathione seperti *GstD8* dan *Gss2*. NPD6990 pula merencatkan tapak jalan tindak balas imun melalui gen seperti *BomS1*, *BomS2* dan *BomS3* yang mengurangkan keradangan saraf yang terlibat dalam patogenesis agregasi amiloid. Secara keseluruhan, penemuan kajian ini membuktikan SalA, SalB dan NPD6990 mempunyai potensi sebagai agen terapeutik untuk AD dan kategori gangguan otak yang lain.

**IN VITRO AND IN VIVO STUDY ON THE IDENTIFICATION OF
COMPOUNDS THAT ALLEVIATE A β 42 ASSOCIATED
NEURODEGENERATION**

ABSTRACT

Alzheimer's disease (AD) is the most common type of neurological disorder globally. Its mechanism includes the distinctive aggregation of extracellular senile plaques made up of amyloid-beta (A β) in the brain. Among the A β isomers secreted in the brain, A β 42 is the most neurotoxic and aggressive. Regardless of the immense research on AD, the full pathogenesis of this disease remains unknown. The main aim of this study was to identify compounds that are able to alleviate A β 42's negative effects. Two groups of compounds, water soluble constituents from Danshen water extract (DWE) and small molecules from RIKEN's NPDepo library were screened. The compounds were first verified to reduce A β 42 aggregation grounded on the *in vitro* A β 42 aggregation assay that quantified the formation of A β 42 aggregates in real-time. Twenty compounds that were able to reduce the amount of aggregated A β 42 to less than 70% of A β 42 controls that were not treated with any compounds were considered potential A β 42 aggregation inhibitors. Since A β 42 aggregation results in neuronal degeneration, the potential A β 42 inhibitors were evaluated on A β 42-incubated PC12 neuronal cells. Six of the inhibitors were able to significantly reduce cell death of A β 42-incubated PC12 cells compared to PC12 control cells that were unexposed to A β 42. These six compounds were then tested on the *Drosophila melanogaster*. The *Drosophila melanogaster* is an excellent model in analyzing both physiological and behavioral features of human

neurodegenerative disorders. The AD *Drosophila* model that expressed the human A β 42 was employed. This AD *Drosophila* demonstrated deteriorated eye structures termed as the rough eye phenotype (REP), declining locomotive ability and early death. Administration of salvianolic acid A (SalA) (100 μ M), salvianolic acid B (SalB) (100 μ M) and NPD6990 (100 μ M) were found to partially ameliorate the REP, enhanced climbing mobility and prolonged the lifespan of AD *Drosophila*. Due to these rescue effects, the transcriptomic responses of AD *Drosophila* towards the three compounds were investigated. SalA inhibited steroid biosynthesis genes such as *Lip3* which could possibly reduce the formation of amyloid plaques in the brain. On the other hand, SalB increases glutathione concentration in the brain that combats oxidative injury exacerbated by A β through the upregulation of genes involved in glutathione synthesis such as *GstD8* and *Gss2*. Alternatively, NPD6990 suppressed the immune response pathway via genes such as *BomS1*, *BomS2* and *BomS3* which reduce neuroinflammation implicated in the amyloid aggregation pathogenesis. In conclusion, the findings here collectively evinced the likelihood of SalA and SalB in addition to NPD6990 as promising therapeutic properties for AD and possibly other categories of brain disorders.

CHAPTER 1

GENERAL INTRODUCTION

1.1 Overview

Ageing is the natural progression of life and is a risk factor to age-associated disorders such as dementia (Franceschi et al., 2018). According to United Nations projections, the global population of 7.35 billion as of 2019 will surpass 10 billion in 90 years (Cabrales et al., 2019). This ageing tsunami brings about complications in the form of age-related diseases.

Alzheimer's disease (AD) is the most common form of dementia and is described as a gradual and progressive decline in cognitive function. While memory decline is the most associated trait of the disease, AD patients often encounter a range of other symptoms such as behavioral deviations to motor decline, and ultimately the inability to perform the simplest tasks (Tarawneh & Holtzman, 2012). Being a multifactorial disease, there have been many hypotheses proposed on the occurrence of AD with the most recognized theory being the accumulation of amyloid-beta ($A\beta$) in the brain (Carmo Carreiras et al., 2013; Tan & Azzam, 2017). Of all the $A\beta$ species synthesized in the brain, $A\beta_{42}$ has been found to be the most toxic and aggressive (Phillips, 2019). However, despite the many decades of research, there has yet to be a cure for AD (Szczechowiak et al., 2019). The very limited United States Food and Drug Administration (FDA)-approved drugs targeted to AD only serve to delay the onset of AD symptoms (Godyń et al., 2016). As we move towards a global ageing population, the need for new and improved medications for AD becomes an increasing necessity.

This study's main focus is to screen for novel natural compounds that possess the ability to negate A β 42's negative effects. On top of using *in vitro* methods to identify A β 42 ligands, PC12 neuronal cells were also utilized as a screening platform. In addition, transgenic *Drosophila melanogaster* carrying the human A β 42 gene was employed as the model organism to assess the compounds of interest for their effect in delaying AD. As the *Drosophila* share a similar yet simpler central nervous system to mammals, *Drosophila* research has made vital breakthroughs in the field of neuroscience (Pandey & Nichols, 2011). With a short lifespan, simple anatomy as well as genetic characteristics that further supports its role as a model for neurodegenerative diseases, the *Drosophila* was the ideal organism for studying specific phenotypes required in this research (Tan & Azzam, 2017).

All in all, this investigation hopes to provide new facets to the underlying pathways of A β 42 mechanism, and reveal novel compounds that work against A β 42 toxicity.

1.2 Objectives

The principal aim of this thesis was to identify compounds that were able to ameliorate Alzheimer's disease. This was subdivided into the following objectives:

- (i) To identify inhibitors of A β 42's aggregation via *in vitro* methods
- (ii) To evaluate the functionality of selected compounds in a neuronal cell culture environment when exposed to A β 42
- (iii) To elucidate the compounds' ability to protect the transgenic *Drosophila melanogaster* AD model from A β 42's ill effects
- (iv) To decipher the response of *Drosophila melanogaster* expressing A β 42 towards the compounds via transcriptomic analysis.

1.3 Outline

This thesis has seven chapters:

The current chapter presents a short overview, experimental objectives, and outlines the entire thesis.

Chapter 2 is an in-depth literature review encompassing current (at the time of writing) knowledge concerning the key casts of this research. It introduces the reader to Alzheimer disease as a problem to the public, what is presently known about its pathogenesis, and A β 42 as an important factor in the disease mechanism. The reader is also given information about the fruit fly, *Drosophila melanogaster*, and how this model organism has contributed to Alzheimer's disease studies.

Chapters 3 to 6 are sections corresponding to individual objectives. Each of these chapters comprises of its own introduction of the topic, materials and methods, results and discussion of that particular investigation. Although later chapters utilize results from their preceding chapters, each chapter is meant to be able to stand-alone as individual mini theses.

Chapter 3 starts with an extensive *in vitro* screening of thousands of compounds, where compounds that were able to reduce the aggregation rate of A β 42 were deemed as potential inhibitors.

In Chapter 4, these potential inhibitors were applied onto neuronal cell culture exposed to A β 42. As not all compounds work similarly in cells as they do in *in vitro* situations, this experiment served as a secondary screening method. Compounds that were able to protect cells from A β 42's effects were brought forward to the subsequent chapter.

Chapter 5 exploits the *D. melanogaster*, whereby transgenic *Drosophila* expressing the human A β 42 gene were orally administered with the candidate compounds. Different behavioral aspects linked to Alzheimer's disease were scrutinized to further clarify the compounds' abilities in ameliorating the disease.

Chapter 6 comprehensively analyzes the pathways by which the compounds operate against A β 42 using Next generation RNA-sequencing. By comparing transcripts from compound-treated transgenic *Drosophila* with the untreated samples, we would then be able to visualize which genes were implicated in the compounds' protective mechanism.

The thesis ends with Chapter 7, which includes a summary of the key findings in the preceding chapters, acknowledging limitations of the study and suggestions for amending them as well as proposals for future studies.

CHAPTER 2

LITERATURE REVIEW

2. Literature Review

2.1 The ageing tsunami– A global concern

The ageing population phenomenon is a global occurrence that has been given massive attention worldwide. Consistent with the World Population Prospects 2019 (Nations, 2019), by the year 2050, the projected ratio of those older than 65 years of age is one in six individuals, which is an increase from the recent ratio of one in eleven individuals in 2019. Similarly, the “old-age” stage, which is defined as the point when the remaining life expectancy decreases to 15 years, is progressively increasing as well (Pison, 2019). Most, if not all societies are currently undergoing this longevity revolution, with some barely stepping into the early stages while others are presently experiencing more advanced phases. Likewise, Malaysia is expected to be an ageing country by 2035, as soon as 15 % of the nation’s population are categorized as senior citizens (Daim, 2019).

Unfortunately, with the surge in elderlies, there has been an increase in common ageing complications that senior citizens worldwide are experiencing. These problems are clustered into two groups: (1) physical and mental health, and (2) financial capability (He et al., 2016).

2.1.2 Ageing and dementia

Neurodegenerative disease is an umbrella term that covers a broad range of chronic or progressive brain conditions that principally affect the neurons in the brain (Ropper et al., 2014). On the other hand, dementia is a symptom of certain

neurodegenerative diseases and is most commonly associated with the deterioration of intellectual aptitudes that is severe enough to disrupt a person's ability to perform daily activities (Ropper et al., 2014). Such decline is occasionally preceded by the loss of emotional control, personality changes, or motivation (Sadock & Sadock, 2011).

The global cost of dementia in 2019 was estimated to be USD 800 billion per annum which was predicted to increase up to USD 2 trillion by 2030 (Chan et al., 2019). The Alzheimer's Disease International (ADI) testified that 46.8 million people globally were affected by dementia, with the total number doubling every 20 years to an estimate total of 74.7 million by the year 2030 (Patterson, 2018). Focusing on Malaysia's elderly population, our nation has an approximate number of 123,000 individuals with dementia which amounts to a total healthcare cost of USD 175 million per year (Prince, 2015). The National Health and Morbidity Survey (NHMS) reported that a total of 8.5 % of Malaysian elderlies over the age of 60 were experiencing dementia (Mustaming et al., 2018).

The highest risk factor for dementia is increasing age. After the age of 65 years, the prevalence and incidence of dementia doubles in every five to six years and around 30 % of individuals aged above 85 years might be affected by dementia (Patterson, 2018). Furthermore, approximately 80 % of reported dementia cases were elderlies aged above 75 years (Fratiglioni & Qiu, 2011). This is a grave problem for the public well-being and health policy development as the oldest senior citizens (for instance the octogenarians, nonagenarians, and centenarians) are the fastest increasing sector of every population. Thus, dementia is and will be a huge burden to the ageing tsunami. However, despite occurring more often with age, it is crucial to understand that dementia is not a part of normal ageing and it is not the

inevitable fate of the elderly. In fact, there have even been reports of “young” onset dementia (occurring prior to the age of 65 years) which makes up 9 % of total records worldwide (Cahill, 2019).

2.2 Alzheimer’s Disease (AD) – The plight of forgetfulness

AD was first discovered by Dr Alois Alzheimer while examining 50 year old Auguste Deter (Alzheimer, 1906). Dr Alzheimer described that Deter was suffering from short-term memory, confusion and disorientation. His autopsy of Deter’s brain identified neurofibrillary tangles, senile plaques and brain atrophy (Cipriani et al., 2011). These brain abnormalities would later be recognized as attributes of AD.

As the most widespread form of dementia worldwide, AD accounts for 40 % to 80 % of documented dementia cases (Nussbaum & Ellis, 2003). Hitting closer to home, approximately 50,000 Malaysians were living with the disorder (Habash et al., 2013). Likewise with dementia, although age is the single paramount risk factor for developing the disease, it is not the direct cause of AD (Dewachter et al., 2000). Individuals at 70 years and above have a 10 % risk of developing AD which increases to 45 % for those aged above 85 years (Bird, 2008). While the disorder is frequently linked with cognition decline, patients often experience a range of other symptoms such as motor dysfunctions and behaviour changes. Regardless of discrepancies in patient symptoms, molecular analysis showed that the genetic makeup of the disease is conserved (Theuns & Van Broeckhoven, 2000). Conversely, environmental factors associated with AD include sleep deprivation, exposure to environmental insults or stressors such as psychological stress, environmental toxins, hypothermia, anesthesia, brain trauma and injury, starvation and glucose hypometabolism (Killin et al., 2016; Wainaina et al., 2014).

2.3 Genetics of AD

There are two classifications of genes that determine the occurrence of a disease: (1) risk genes and (2) deterministic genes. Both types were identified in AD pathogenesis. Risk genes raises the likelihood of developing a disease while triggering the emergence of symptoms but does not guarantee the manifestation of the disease (Karch & Goate, 2015). On the other hand, deterministic genes are genes that directly cause the disease, therefore guaranteeing the development of the disease when inherited. These genes accounts for 5 % of AD cases whereby individuals experience familial early-onset forms of AD (Reitz & Mayeux, 2014). In contrast, the majority of AD patients are diagnosed with late-onset disease (Zou et al., 2014).

There are multiple motives for studying the genetic etiology of AD and its connection to AD neuropathology: 1) Unravelling the underlying genetics leads to a deeper understanding of the disease pathophysiology. 2) Distinct from most environmental risk factors, genetic risk factors may be modifiable. 3) Genetic risk factors are potential drug targets and thus allow for the production of personalized disease treatments. 4) Genetic risk factors can be utilized as biomarkers to detect at risk populations for early disease prevention.

2.3.1 Early onset familial Alzheimer's disease (EOFAD)

AD associated to genetic causes is known as early onset familial Alzheimer's disease (EOFAD). Fortunately, while EOFAD is more severe and progresses rapidly, the manifestation of EOFAD is relatively rare; making up about 5 % of all AD cases (Bagyinszky et al., 2014). EOFAD is inherited through autosomal-dominance and has a large multi-generational lineage that facilitates genetic analysis. Furthermore, the occurrence of symptoms prior to the age of 65 allows for early detection (Bird,

2008). The three main genes associated with EOFAD are part of the amyloid pathology: amyloid-beta precursor protein (*APP*) (Goate et al., 1991), presenilin 1 (*PSEN1*) (Sherrington et al., 1996) and presenilin 2 (*PSEN2*) (Schneider et al., 2014). These genes affect the processing or production of A β , the main component of amyloid plaques seen in Alzheimer's disease patients (Bagyinszky et al., 2014). Mutations in both *APP* and *PSEN2* account for less than 20 % of the total EOFAD cases, while *PSEN1* mutations were discovered in 80 % of EOFAD patients (Hutton & Hardy, 1997).

2.3.1(a) Amyloid precursor protein (APP)

The amyloid precursor protein (*APP*) gene encodes for a fundamental membrane-related type-1 transmembrane protein that is made up of a sizable extracellular amino terminal region and a minor intracellular cytoplasmic region (Nilsberth et al., 2001). The extracellular region covers a cysteine-rich sub-domain adjacent to the amino terminal, an acidic sub-domain and another two sub-domains, of which one has alleged neuroprotective properties (Nilsberth et al., 2001). *APP* contains 19 exons across 290 kb which encodes for a protein approximately 695-770 amino acid long (Zheng & Koo, 2006). The A β protein is encoded by exons 16 and 17 (Yoshikai et al., 1990). *APP* is found on chromosome 21 in humans. Indeed, Down syndrome patients carrying an extra chromosome 21 also demonstrated AD-like symptoms (Wisniewski et al., 1985). The *APP* gene expression typically takes place in cells and tissues of the neurons, glia and endothelia in the brain. No less than three major protein conformers, APP695, APP751 and APP770 are cut alternatively from the *APP* pre-mRNA (Tomiyama et al., 2008). The protein, APP is located in the cell membrane, Golgi compartments and endoplasmic reticulum (Schellenberg et al.,

1992). During normal neuronal function, APP behaves as a G-protein-coupled receptor that assists in synaptic plasticity and transmission as well as cell adhesion (Nilsberth et al., 2001).

As of now, there are 33 different *APP* mutations recognized in AD patients: 1 deletion, 9 duplications and 23 missense mutations (Hutton & Hardy, 1997) (Known *APP* mutations are shown in Figure 2.1). As the mutations are dominantly inherited, they are found close to or within the β -secretase and γ -secretase splice sites in exons 16 and 17 of the *APP*; hence, these mutations impact the resulting protein's proteolytic processing, C-terminal fragment stability and aggregation of APP C-terminal fragments and A β aggregation (Kovacs et al., 1996). Table 2.1 shows the different *APP* mutations. While clinical symptoms of mutation carriers differs, all *APP* mutations have modified APP proteolytic processing that either brings about an upsurge in total A β production or A β 42 compared to wild-type APP which leads to an overall increase in A β 42/A β 40 ratio (Nilsberth et al., 2001).

Table 2.1: List of mutations near to or within the A β region of the APP

Type/location of mutation	Mutation name	Reference
Double mutation at the N-terminal of the A β region near to the β -secretase site	<i>KM670/671NL</i> (Swedish mutation)	(Fukumori et al., 2010)
C-terminal of the A β region close to the γ -secretase cleavage site	<i>T714A</i> (Iranian mutation) <i>T714I</i> (Austrian mutation) <i>V715M</i> (French mutation) <i>V715I</i> (German mutation) <i>I716V</i> (Florida mutation) <i>V717I</i> (London mutation) <i>K724N</i> (Belgian mutation) <i>L723P</i> (Australian mutation) <i>I716F</i> (Iberian mutation) <i>V717F</i> (Indiana mutation)	(Kim et al., 1997) (Thinakaran et al., 1996) (Janssen et al., 2003) (Vetrivel et al., 2006) (Van Cauwenberghes et al., 2016) (Goate et al., 1991) (Sherrington et al., 1996) (Shen et al., 1997) (Guerreiro et al., 2010) (Murrell et al., 1991)
Point mutations located within the A β coding domain	<i>A692G</i> (Flemish mutation) <i>E693K</i> (Italian mutation) <i>E693Q</i> (Dutch mutation) <i>E693G</i> (Arctic mutation) <i>D694N</i> (Iowa mutation)	(Wong et al., 1997) Cruts & Van Broeckhoven, 1998) (Farrer et al., 1990) (Myers et al., 1996) (Kayden et al., 1985)
Deletion mutation at APP 693	$\Delta E693$ (Osaka mutation)	(Tomiyama et al., 2008)




Figure 2.1: Pathogenic mutations within the A β region of the APP. Adapted from (Janssen et al., 2003).

2.3.1(b) Presenilin (PS)

Besides APP gene mutations, changes in presenilin genes are also implicated in AD pathogenesis. Presenilins (PS) that encode the *PSEN* genes are transmembrane region proteins which make up part of the catalytic subunits of the γ -secretase intramembrane protease complex (Iwatsubo, 2004). The human *PSEN1* and *PSEN2* genes are located on chromosome 14 (Schellenberg et al., 1992) and chromosome 1 (Levy-Lahad et al., 1995), correspondingly. The PS-1 protein is a 42- to 43 kDa polypeptide (Thinakaran et al., 1996) while the PS-2 protein has a size of 53-55 kDa (Kim et al., 1997). The presenilin proteins are spliced by unknown proteases in the α -helical sequence of the cytoplasm loops which leads to a protein with a larger N-terminal portion and a minor C-terminal fragment. Consequently, the two fragments are fused to form a functional protein (Hutton & Hardy, 1997). The *PSEN1* gene has a significant role in intra-membrane mediation and encodes a serpentine protein which is generally found in the Golgi apparatus, endoplasmic reticulum and nuclear envelope (Fukumori et al., 2010; Kovacs et al., 1996). RNA transcripts of *PSEN1* can be found in the human heart, placenta, pancreas, kidney, skeletal muscle and brain (Kovacs et al., 1996). In contrast, *PSEN2*'s exact role is still a mystery; however, it is presumed that proteins of *PSEN2* and *PSEN1* work together as constituents for γ -secretase (Vetrivel et al., 2006). As γ -secretase is involved in APP splicing that generate A β 40 and A β 42 fragments, changes in either presenilins will cause the proliferation of secreted A β 42 or reduce the concentrations of A β 40 (Cruts & Van Broeckhoven, 1998).

2.3.2 Late onset Alzheimer's disease (LOAD)

There is a strong genetic basis for late-onset Alzheimer's disease (LOAD); thus far, 22 genes/loci that affect the risk of LOAD have been identified. LOAD inheriting families have low kin survivability at the particular onset period as well as being low in genetic data of the parents. In a study assessing 70 families with one or more AD patients, the offspring of AD patients had an expected lifetime risk of 53 % in EOAD families versus LOAD family kin that had an 86 % risk (Farrer et al., 1990). This outcome reinforced that EOAD is autosomal dominantly transferred to the kin while LOAD had a heterogeneous transmission with a combination of genetic, environmental and lifestyle contributions (Zou et al., 2014).

Out of all LOAD cases, 15 % of patients carry an Apolipoprotein E (*APOE*) allele (Myers et al., 1996). *APOE* is located at chromosomal locus 19q13.2 and codes for a glycoprotein the size of 299 amino acids. It is produced in the monocytes, resident macrophages, liver, and brain of humans (Kayden et al., 1985). *APOE* protein acts as a transport for lipids and also functions in lipolytic enzyme activation, neuronal growth, immune-regulation and repair of tissues (Van Cauwenberghe et al., 2016). In addition, *APOE* also contributes to the re-modeling and repairing neurons through various pathways such as the anti-oxidation, oestrogen interaction and synaptodendritic proteins regulation (Khanahmadi et al., 2015). Mouse studies have shown that *APOE* is involved in the production of neuritic and cerebrovascular plaques (Holtzman et al., 2000). *APOE* also plays a role in A β homeostasis in the brain by mediating both the accumulation and removal of A β (Verghese et al., 2013).

Interestingly, certain Nigerian populations do not show any association between *APOE4* and AD age-of-onset as seen in other populations (Gureje et al., 2006). This suggested that there is incomplete penetrance of *APOE* and also the

involvement of other genes in LOAD. The human brain possesses three *APOE* alleles that are located at the same gene locus ($\epsilon 2$, $\epsilon 3$ and $\epsilon 4$) encoding for isoforms *APOE2*, *APOE3* and *APOE4*, respectively (Roses, 1996). These isoforms are structurally distinguishable by two amino acid substitutions at residues 112 and 158: *APOE3* carries Cys112 and Arg158; in *APOE2*, cysteine substitutes Arg158, while arginine substitutes Cys112 in *APOE4* (McKeon-O'Malley & Tanzi, 2001). These differences in amino acid positioning affect *APOE* function by altering the structure and charge of the respective protein (Verghese et al., 2013).

Carriers of the $\epsilon 4$ allele tend to inherit both early and late onset AD (Corder et al., 1993). There is an expected threefold risk of developing AD for $\epsilon 34$ genotype heterozygous carriers while homozygous carriers of $\epsilon 4$ allele have a 15-fold risk (Farrer et al., 1997; Saunders et al., 1993). Additionally, $\epsilon 4$ allele carriers have an amplified risk from two to five fold with an earlier onset age of 7.7 years compared to homozygous $\epsilon 3$ allele carriers (Corder et al., 1993). On the other hand, carriers of the $\epsilon 2$ allele had a delayed onset age of AD symptoms (Corder et al., 1993). Each *APOE* allele affects the concentration of $A\beta 42$ secreted in the brain with $\epsilon 4$ having the highest concentration of $A\beta 42$ produced, followed by $\epsilon 3$ and finally $\epsilon 2$ (Castellano et al., 2011). Homozygous carriers of the $\epsilon 4$ allele generally develop AD by 80 years old (Corder et al., 1993).

2.4 Amyloid pathway hypothesis

The construction of the amyloid pathway hypothesis, otherwise known as the amyloid cascade hypothesis, was compiled from various data founded from the chronological events – (1) the earliest record in 1906 of senile plaques and neurofibrillary tangles (NFTs) by Dr Alois Alzheimer from his autopsy of an AD

patient's brain (Alzheimer, 1906), (2) the successful extraction of A β from senile plaques in 1984 (Glennner & Wong, 1984), (3) sequencing of the *APP* gene in 1987 (Kang et al., 1987) (4) discovery of *APP* autosomal dominant mutations (Goate et al., 1991). (5) proposal of the amyloid pathway hypothesis in 1992 (Hardy & Higgins, 1992) that was reappraised in 2006 (Hardy, 2006). This theory suggested that the manifestation of AD was because of two types of genetic mutations: LOAD and EOFAD.

2.4.1 A β production, oligomerization and fibrillization

Total cellular APP's half-life is short of about 30 to 60 mins (Storey et al., 1999) and its post-translational processing consists of two pathways (Figure 2.2). In the non-amyloidogenic pathway, α -secretase begins by cleaving within the A β sequence (between residues Lys687 to Leu688) which causes A β to be inactive and non-toxic peptides are produced (McKeon-O'Malley & Tanzi, 2001). Splicing by γ -secretase at the residual C-terminal extracellularly secretes the non-toxic P3 peptide whereas the APP intracellular domain (AICD) is retained in the cell (Hardy, 1997). Conversely, the amyloidogenic pathway involves the cleavage of APP by β -secretase directly at A β 's N-terminal (between residues Met671–Asp672) (Hardy, 1997). Additional splicing by γ -secretase at A β 's C-terminal yields a functional A β peptide that is excreted out of the cell (Prüßing et al., 2013). Due to γ -secretase's heterogeneous splicing nature, various lengths of A β species are secreted (O'Brien & Wong, 2011).

A β 's self-aggregation is affected by its sterics, secondary structure propensity, charge, and hydrophobicity (Senguen et al., 2011). Due to A β 's self-assembly features, A β 's soluble monomers can have various mis-folding

arrangements that produce different concentrations of protein aggregates either under or near physiological environments. In addition, specific mis-folded oligomers, termed as “seeds”, are able to induce other A β to mimic the mis-folded oligomeric structure. This causes a chain reaction similar to a prion infection (Haass & Selkoe, 2007). A β 's aggregation kinetics is reliant on the C-terminal residues, therefore, A β 42 experiences a more rapid fibrillization compared to A β 40. In fact, the presence of A β 42 peptides hastens A β 40 fibrillization (Jarrett et al., 1993). This supports findings wherein familial EOFAD brains have elevated A β 42 to A β 40 ratio levels compared to healthy brains of the same age range (Scheuner et al., 1996).

Generally, A β fibril formation starts with a lag phase, whereby a thermodynamically stable nucleus is required to aggregate and is succeeded by a rapid elongation phase (Harper & Lansbury Jr, 1997). This results in the formation of large insoluble amyloid fibrils that are anti-parallel and cross- β -sheet in structure (Lee & Ham, 2011). However, the exact A β species that is responsible for neurotoxicity to the AD brain has yet to be determined.




Figure 2.2: APP proteolysis. The left portion depicts the non-amyloidogenic pathway wherein APP is first cut by α -secretase and consecutively by γ -secretase to produce the non-toxic P3 peptide and AICD fragment. On the right, the amyloidogenic pathway consists of β -secretase splicing of APP and consecutively by γ -secretase to yield A β peptides. A β peptides undergo oligomerization, fibrilize and finally produce insoluble plaques. Adapted from (Tan & Azzam, 2017).

2.4.1(a) A β proteins – its normal physiology and toxic forms

The A β protein was first acknowledged as a potential biomarker of AD when it was discovered as “a novel cerebrovascular amyloid protein” in 1984 (Glenner & Wong, 1984). The following year, this 4.2 kDa protein was recognized as a main component of senile plaques in AD brains (Wong et al., 1985). The size of A β varies between 39 to 43 amino acid residues, all of which are produced in the AD brain (Hamley, 2012).

A β 40 is the most prominent conformer followed by A β 42 in both normal and AD human brains (Seubert et al., 1992). Compared to A β 40, A β 42 has an extra isoleucine and an extra alanine at the C-terminal. Despite the high similarity in sequence identity, A β 40 is lower in amyloidogenicity but higher in solubility than

A β 42 (Snyder et al., 1994). The early structures and stabilities of A β 42 and A β 40 are distinctive from each other with A β 40 occurring as monomers while A β 42 exists as equal amounts of trimer/tetramer and monomers (Sgourakis et al., 2007). A β 40 and A β 42 undergo different fibrillization pathways, whereby A β 42 produce pentameric/hexameric paranuclei while A β 40 experiences monomer accumulation (Bernstein et al., 2009). A β 42's higher hydrophobicity is most likely the reason why it is able to integrate into the lipid bilayer which thus leads to cell injury (Butterfield et al., 2013). In addition, A β 42's more structured C-terminal may aid its tendency to aggregate (Lim et al., 2007). A β 40 has been shown to inhibit aggregation of A β 42 by preferentially binding onto A β 42 proto-fibrils (Yan & Wang, 2007). Changes in A β 42 to A β 40 ratio leads to different neurotoxicity intensities (Kuperstein et al., 2010). A β 40 is primarily linked to cerebral amyloid angiopathy (DeSimone et al., 2017), while A β 42 is the main constituent in amyloid plaques and has a higher correspondence with AD pathology (Roses, 1998).

While A β has been implicated in AD pathology, the protein exists in normal brains albeit at low concentrations (Cirrito et al., 2003). From this, it is highly likely that A β is required for normal physiological function in the brain specifically in moderating synaptic activity and neural survivability (Pearson & Peers, 2006). A β 's nature to be either ameliorating or aggravating depends on both its relative concentration and also the cellular environment it resides in (Parihar & Brewer, 2010). Increased A β concentrations (nM to μ M) resulted in neurotoxicity and neuronal death (Jellinger, 2006). Contrariwise, low concentrations of A β , in pM, served as trophic signals and as a mediator of synaptic activity in addition to modulating neuron cell viability (Plant et al., 2003). At this low amount, A β was found to act as antioxidants that latched onto redox-active metals such as zinc and

iron. This binding was shown to inhibit these metals from redox cycling with other ligands (Atwood et al., 2003).

A β 's concentrations in the brain is affected by an equilibrium of several considerations: (1) the modulation of APP cleavage and A β construction, (2) A β removal and facilitation of A β through the blood-brain barrier, (3) proteolytic degradation of A β , (4) oligomerization of A β and (5) the aptitude of A β to latch onto and sequester other A β proteins, which consecutively governs A β aggregation and clearance. Accordingly, the disruption of the homeostatic state between A β secretion and its elimination will possibly cause the onset of AD (Bates et al., 2009). Besides that, modifications to A β 's structure from post-translational dysregulations might also hasten AD's pathological events (Parihar & Brewer, 2010).

The discovery of amyloid deposits in senile plaques of all AD human brains prompted the hypothesis of amyloid cascade whereby AD onset is caused by the aggregation of soluble A β into insoluble fibrils. Fresh A β is non-toxic. However, amyloid fibrils were found to cause neurotoxicity by amplifying the number of both the action potentials and depolarisation of the membrane in cell cultured neurons (Howlett et al., 1995; Kowall et al., 1991; Lorenzo & Yankner, 1996). Furthermore, rats with compromised synaptic transmission demonstrated cognitive or memory dysfunction and death of neurons when injected with amyloid fibrils into the rat dorsal dentate gyrus (Stephan et al., 2001). Fibrillar A β has also been proven to bind to various cell surface proteins, as well as the receptor for advanced glycation end products (RAGE) complex and APP. These bindings cause a surge in free radical production and oxidative stress (Verdier & Penke, 2004). Likewise, the binding of A β fibrils to the α -7 nicotinic receptor modulate N-methyl-D-aspartate (NMDA) receptor results in defects towards cellular metabolism including the loss of synaptic

function that is implicated in symptomatic AD (Snyder et al., 2005). Some studies exhibited that the progression and severity of AD is reliant on the concentration of aggregated insoluble A β fibrils (Lorenzo & Yankner, 1996; Meyer-Luehmann et al., 2008). A distinguishing feature of A β fibrils is that the same type of fibril can have various morphologies based on the aggregation environments (Petkova et al., 2002; Xu et al., 2014). Such manifestations are termed as A β fibrils polymorphism which greatly influences the neurotoxicity of the fibrils (Petkova et al., 2002).

On the other hand, amyloid plaques are the abnormal, proteinaceous, fibrous deposits with diameters between 7 to 10 nm and a β -sheet secondary formation (Sunde et al., 1997). These plaques are largely made up of A β proteins and A β -related proteins such as vitronectin, apolipoprotein J, APOE, α 1-antichymotrypsin and other non-A β constituents (Yamaguchi, 1999). There are two types of amyloid plaques often seen in AD – diffuse plaques and dense core plaques (Thal et al., 2006).

Diffuse plaques are found at first in the neuropil and are weakly stained by Thioflavin S (THS) and amyloidophilic dyes such as Congo red (Teplow et al., 2012). It is understood that diffuse plaques occur prior to senile plaques (Gyure et al., 2001). In their early formation, diffuse plaques are amorphous instead of fibrils (Yamaguchi, 1999). At their later stages, production of low amounts of fibrillary A β are detected between cell processes (Yamaguchi, 1999). Compared to diffuse plaques, senile plaques have a dense reticular amyloid core that is rich in long A β proteins. Since senile plaques are denser with abundant fibrils, they are intensely stained positive with THS and Congo red (Teplow et al., 2012).

It has been revealed that microglia associate with amyloid plaques (Mandrekar-Colucci & Landreth, 2010). A β , either in the protomeric or oligomeric stages, may

be the main factor prompting the activation of microglia which causes an abnormally vigorous neuroinflammatory reaction (Garden & Möller, 2006). The gliosis and neuroinflammation derived from the aggregation of A β protein is itself neurotoxic (Leyns & Holtzman, 2017). Amyloid plaques in the brains of AD patients are generally surrounded by activated microglia, which implies that the cytokines and cytotoxic molecules secreted by microglia may function in the disease pathogenesis (Jung et al., 2015).

2.5 Animal models of AD

It is undisputable that human genetic research has enhanced our comprehension on genes related to neurodegeneration. Nevertheless, investigations on human subjects are limited by ethical and technical restrictions. As such, we look to animals to mimic human diseases. AD models comprise of the fruitfly (*Drosophila melanogaster*), mouse (*Mus musculus*), zebrafish (*Danio rerio*), and nematode (*Caenorhabditis elegans*); each emulating different aspects of AD (Table 2.2).

Table 2.2: Evaluation of common animal models. Adapted from (Tan & Azzam, 2017).

Organism	Advantages	Disadvantages
<i>Mus musculus</i> (Mouse)	<ul style="list-style-type: none">• Mammal brain anatomy similar to humans• Sophisticated behavioural analysis• Histopathology testing accessible• Targeted gene replacement available	<ul style="list-style-type: none">• Relatively expensive• Long life-cycle• Complex gene manipulation procedures• Ethical considerations• Laborious• Inefficient
<i>Caenorhabditis elegans</i> (Roundworm)	<ul style="list-style-type: none">• Relatively inexpensive• Short life cycle• Small size• Large population• Genomics known	<ul style="list-style-type: none">• Poor illustration of some signalling pathways• Retains fewer gene homologs in mammals• Lacking in many vital organs available in humans• No male/female sexual system• Brain is not centralized• Challenging to evaluate behavioural abnormalities
<i>Danio rerio</i> (Zebrafish)	<ul style="list-style-type: none">• Simple vertebrate structure• Transparency permits easy observation• External embryos• Excellent organogenesis model	<ul style="list-style-type: none">• Relatively expensive• Long life cycle• Genetics and genomics studies still developing

2.5.1 *Drosophila melanogaster*: A comprehensive model

The *Drosophila melanogaster*, otherwise known as the fruit fly, has contributed tremendously to genetics and neuroresearch. Presently, there are *Drosophila* models for most neurodiseases including AD, Huntington's disease, motor-neural disease, transthyretin-related amyloidotic polyneuropathy and polyQ-associated expansion conditions (Moloney et al., 2010).

Thomas Hunt Morgan first introduced *Drosophila* into the field of genetics in 1908. It was Thomas' suspicions in Gregor Mendel's laws of inheritance that led Thomas to dabble in *Drosophila* research where he ultimately discovered the theory of genes as the carrier of hereditary information (Morgan, 1910).

The *Drosophila*'s genome size of about 175 Mb with approximately 13,600 genes (Ellis et al., 2014) is minuscule in contrast to the human genome of approximately 50,000 genes (Alles et al., 2019). Out of the 287 documented human disease genes, 197 (69%) have a *Drosophila* homolog (St Johnston, 2002). Moreover, *Drosophila* have fewer genetic redundancy than vertebrate models, making gene characterization less complex.

There are many assets that make *Drosophila* such an attractive organism to observe. The fruit fly has a short lifespan and is regarded as a four-in-one model due to its life history that comprises of distinguishable morphological phases: the embryo, larva, pupa and adult, each providing distinct modelling purposes (Pandey & Nichols, 2011). Moreover, care and housekeeping requires little equipment with low overall cost.

Drosophila's simple anatomy and genetic features benefit it in its role as an exemplary disease model. There is neither meiotic recombination nor synaptonemal complex in male *Drosophila* (Orr-Weaver, 1995; St Johnston, 2002). Therefore,

recombinant manipulation is concentrated only on females. Differentiating males and females can be efficiently done under the light microscope due to their obvious anatomical distinctions. In addition, a single female lays hundreds of offspring within a day, making it easy for large scale genetic screening experiments. *Drosophila* have four pairs of chromosomes that can be easily observed as huge polytene chromosomes whereby denser areas represents transcription activity. Furthermore, the use of balancer genes that function to halt heterozygous recombination has also assisted *Drosophila* studies (Bourguet et al., 2003).

Besides that, *Drosophila*'s brain is a similar albeit less complex central nervous system compared to vertebrates. Both systems comprise of neurons and secondary glia with identical neurotransmitters that are secured by a blood-brain barrier. This proves that the rudimentary principles of the neural system are well-maintained from invertebrates to vertebrates. The *Drosophila* model also displays cellular processes that are required in neurodegeneration such as oxidative stress. Complicated age-dependent behaviours including memory and locomotor capability can also be observed in the *Drosophila* (McGurk et al., 2015).

To develop the *Drosophila* into an AD model, researchers integrated the UAS-GAL4 system into the fly (Figure 2.3). The yeast-extracted transcription factor GAL4 is linked to a tissue-specific promoter gene that is already present in the *Drosophila*. Conversely, the yeast galactose upstream activator sequence (UAS) which is activated by GAL4, is attached upstream from the human disease gene (Fischer et al., 1988). To allow for various genetic recombinations, UAS and its partner gene are inserted into a *Drosophila* line that lacks the GAL4 sequence. Mating of these two lines will generate offspring that express the human disease protein in desired tissues. GAL4 driver lines that are commonly used in neurotoxicity